stockrowRecursion Pharmaceuticals, Inc.
RXRX Healthcare Biotechnology
Recursion Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.7 million, up 26.9% from fiscal 2024.
- Revenue
- +258.5%
- EPS
- +39.1%
- Free cash flow
- +33.8%
- Total debt
- −99.2%
Quarter to September 2026, against a year earlier
Follow RXRX
Alert me
Recursion Pharmaceuticals, Inc. (RXRX) EBITDA
Recursion Pharmaceuticals, Inc.'s EBITDA for fiscal 2025 was −$564.4M, compared with −$442.5M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$421.1M. Over the past ten years it has ranged from −$564.4M (fiscal 2025) to −$58.9M (fiscal 2019) — the current reading is the lowest in ten years. EBITDA has fallen for 7 consecutive fiscal years. Recursion Pharmaceuticals, Inc. ranks 571st of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$564.4M | — |
| FY2024 | −$442.5M | — |
| FY2023 | −$325.7M | — |
| FY2022 | −$234.0M | — |
| FY2021 | −$174.4M | — |
| FY2020 | −$80.7M | — |
| FY2019 | −$60.0M | — |
| FY2019 | −$58.9M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | −$106.6M | — |
| Jun 2026 | −$116.8M | — |
| Mar 2026 | −$108.8M | — |
| Dec 2025 | −$88.9M | — |
| 23 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ADMA ADMA Biologics Inc compare | $232.8M |
| VCEL Vericel Corporation compare | $31.3M |
| PVLA Palvella Therapeutics, Inc. compare | −$57.7M |
| MBX MBX Biosciences, Inc. compare | −$117.7M |
| PHVS Pharvaris N.V. compare | −$212.2M |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$233.2M |
| CLDX Celldex Therapeutics, Inc. compare | −$326.7M |
| RXRX Recursion Pharmaceuticals, Inc. | −$421.1M |
| BHVN Biohaven Ltd. compare | −$515.1M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on RXRX
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement